+44 (0) 20 7079 4399
Call HCA from 8am-8pm Mon-Fri and 9am-5pm Sat
HCA Healthcare UK
Professor Mohammad Keshtgar
BSc, MBBS, FRCSI, FRCS (Gen), PhD
General Surgery, Breast cancers, Breast Surgery
My vision is for one day in the near future for breast cancer to be treated without cutting it out'Professor Keshtgar is a Consultant Surgical Oncologist with major interest in Breast Cancer. His research theme is Minimally Invasive Approaches in Diagnosis and Treatment of Breast Cancer through innovations. He was one of the pioneers of sentinel node biopsy in the UK and has conducted several clinical projects, and has supervised many students towards MD/PhD and has published extensively in this field including the 1st reference textbook on this subject. He has also made a significant contribution in teaching and training of this technology through running numerous training courses on behalf of the Royal College of Surgeons of England. He has also served as the Advisor to the IAEA at the UN on implementation of this technology in developing countries. His work on optical diagnosis of cancer in sentinel node was recipient of Medical Innovations Award in 2009.He has been actively involved in Intra-operative Radiotherapy in Breast Cancer and has been member of the TARGIT International Steering Committee and scientific advisory board within the UCL Clinical Trials Group. He is the local PI of the TARGIT trials at the Royal Free hospital. He also Co-directs the TARGIT ACADEMY, which is responsible for teaching and training of this innovative technology and has run numerous international training courses with participation from Institution from all 5 continents.He was successful in setting up the first Breast PET scanner in the UK at the Royal Free Breast Unit, which has brought us closer to functional and molecular imaging of the breast cancer. He has recently been awarded a Welcome Trust grant on the use of PET technology intra-operatively for identification of cancer in sentinel node.He is the Chief Investigator of the clinical trial on the role of photodynamic therapy (PDT) in treatment of primary breast cancer and is leading a proof of principle dose escalation study on this important technology. He is also the Chief investigator for the European FP7 funded PICTURE project which aims to create a digital breast surgery and bring us closer to improved objective decision making and communication to patients.He is a fully trained Oncoplastic Breast Surgeon. His main clinical interest is minimally invasive surgery in treatment of Breast Cancer. His is expert in performing endoscopic (key hole) mastectomy, nipple endoscopy and electrochemotherapy. He has published over 200 peer reviewed publications and 5 textbooks in various aspects of breast cancer. He has been invited speaker in major cancer conferences in over 20 countries. Professor Keshtgar's profile published in The Lancet as the Pioneering Surgical Oncologist.
Call the contact centre
+44 (0) 20 7079 4399
8am-8pm Mon-Fri, 9am-5pm Sat
Let us call you backCan we call you back at a more convenient time
Email contact centreSend us an email and we will get back to you.
© copyright 2008 - 2017 HCA Healthcare UK.
Registered Name: HCA International Limited; The part of the UK in which it is registered: England and Wales;
Registered Number: 03020522; Registered Office Address: 242 Marylebone Road London NW1 6JL.
£500m has been invested by HCA International in the latest medical technologies and facilities over the last 10 years.
Your hospital will be one of our world-class private hospitals: HCA’s world-class hospitals are accredited by The CHKS Accreditation Unit, a leading provider of healthcare intelligence and quality improvement services. The accreditation is a measure of the overall quality of a hospital and hospitals with CHKS accreditation have been shown to provide a better quality of service.
Your safety will be protected because we have more critical care beds than any other private hospital group: HCA hospitals achieved 100% compliance with all Care Quality Commission inspected outcomes of care in 2011.
Your treatment will be undertaken using the most advanced diagnostic and treatment facilities: Oliver Wyman, Corporate Accounts: Driving quality and value, January 2012.